Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (11): 1070-1074.DOI: 10.3969/j.issn.1673-8640.2025.11.007
Previous Articles Next Articles
CHEN Zhijin, WANG Yuting, ZHENG Haiyin, LIU Qingzhong(
)
Received:2024-08-22
Revised:2025-05-13
Online:2025-11-30
Published:2025-12-12
CLC Number:
CHEN Zhijin, WANG Yuting, ZHENG Haiyin, LIU Qingzhong. Preliminary establishment of the reference range for cytokeratin 19 fragment and analysis of related factors[J]. Laboratory Medicine, 2025, 40(11): 1070-1074.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.11.007
| 组别 | 例数 | CYFRA21-1/(ng·mL-1) | ||||
|---|---|---|---|---|---|---|
| P2.5 | P5 | P95 | P97.5 | M(P25,P75) | ||
| ≤40岁组 | 373 | 0.89 | 1.01 | 3.47 | 3.92 | 1.80(1.42,2.39) |
| 男 | 269 | 0.94 | 1.10 | 3.37 | 3.96 | 1.87(1.46,2.39) |
| 女 | 104 | 0.82 | 0.88 | 3.69 | 4.09 | 1.69(1.26,2.40) |
| H值 | -0.857 | |||||
| P值 | 1.000 | |||||
| 41~60岁组 | 301 | 0.96 | 1.05 | 4.08 | 5.82 | 2.13(1.65,2.85)* |
| 男 | 222 | 1.01 | 1.08 | 4.14 | 5.89 | 2.29(1.74,2.98)∆ |
| 女 | 79 | 0.86 | 0.97 | 3.84 | 5.87 | 1.85(1.41,2.33) |
| H值 | 3.608 | |||||
| P值 | 0.005 | |||||
| ≥61岁组 | 958 | 1.23 | 1.36 | 4.97 | 5.76 | 2.70(2.03,3.44)*# |
| 男 | 804 | 1.26 | 1.38 | 5.05 | 5.76 | 2.72(2.05,3.46)∆▲ |
| 女 | 154 | 1.06 | 1.27 | 4.83 | 6.11 | 2.63(1.82,3.24)∆▲ |
| H值 | 0.079 | |||||
| P值 | 1.000 | |||||
| 合计 | 1 632 | 1.03 | 1.16 | 4.67 | 5.49 | 2.35(1.74,3.15) |
| 组别 | 例数 | CYFRA21-1/(ng·mL-1) | ||||
|---|---|---|---|---|---|---|
| P2.5 | P5 | P95 | P97.5 | M(P25,P75) | ||
| ≤40岁组 | 373 | 0.89 | 1.01 | 3.47 | 3.92 | 1.80(1.42,2.39) |
| 男 | 269 | 0.94 | 1.10 | 3.37 | 3.96 | 1.87(1.46,2.39) |
| 女 | 104 | 0.82 | 0.88 | 3.69 | 4.09 | 1.69(1.26,2.40) |
| H值 | -0.857 | |||||
| P值 | 1.000 | |||||
| 41~60岁组 | 301 | 0.96 | 1.05 | 4.08 | 5.82 | 2.13(1.65,2.85)* |
| 男 | 222 | 1.01 | 1.08 | 4.14 | 5.89 | 2.29(1.74,2.98)∆ |
| 女 | 79 | 0.86 | 0.97 | 3.84 | 5.87 | 1.85(1.41,2.33) |
| H值 | 3.608 | |||||
| P值 | 0.005 | |||||
| ≥61岁组 | 958 | 1.23 | 1.36 | 4.97 | 5.76 | 2.70(2.03,3.44)*# |
| 男 | 804 | 1.26 | 1.38 | 5.05 | 5.76 | 2.72(2.05,3.46)∆▲ |
| 女 | 154 | 1.06 | 1.27 | 4.83 | 6.11 | 2.63(1.82,3.24)∆▲ |
| H值 | 0.079 | |||||
| P值 | 1.000 | |||||
| 合计 | 1 632 | 1.03 | 1.16 | 4.67 | 5.49 | 2.35(1.74,3.15) |
| 项目 | Spearman相关分析 | 偏相关分析① | |||
|---|---|---|---|---|---|
| r值 | P值 | r值 | P值 | ||
| 年龄 | 0.371 | <0.001 | |||
| AFP | 0.053 | 0.031 | 0.006 | 0.812 | |
| ALT | -0.001 | 0.980 | 0.030 | 0.219 | |
| CEA | 0.266 | <0.001 | 0.114 | <0.001 | |
| TC | -0.037 | 0.136 | -0.043 | 0.082 | |
| SCr | 0.191 | <0.001 | 0.198 | <0.001 | |
| FPG | 0.281 | <0.001 | 0.160 | <0.001 | |
| TG | 0.090 | <0.001 | 0.028 | 0.252 | |
| WBC计数 | 0.104 | <0.001 | 0.088 | <0.001 | |
| 项目 | Spearman相关分析 | 偏相关分析① | |||
|---|---|---|---|---|---|
| r值 | P值 | r值 | P值 | ||
| 年龄 | 0.371 | <0.001 | |||
| AFP | 0.053 | 0.031 | 0.006 | 0.812 | |
| ALT | -0.001 | 0.980 | 0.030 | 0.219 | |
| CEA | 0.266 | <0.001 | 0.114 | <0.001 | |
| TC | -0.037 | 0.136 | -0.043 | 0.082 | |
| SCr | 0.191 | <0.001 | 0.198 | <0.001 | |
| FPG | 0.281 | <0.001 | 0.160 | <0.001 | |
| TG | 0.090 | <0.001 | 0.028 | 0.252 | |
| WBC计数 | 0.104 | <0.001 | 0.088 | <0.001 | |
| [1] | 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231. |
| [2] |
吴晓燕, 朱自力, 张金业. 肿瘤标志物检测在肺癌诊断中的临床应用价值探讨[J]. 检验医学, 2014, 29(5):578-580.
DOI |
| [3] |
NAKAYAMA M, SATOH H, ISHIKAWA H, et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases[J]. Chest, 2003, 123(6):2001-2006.
PMID |
| [4] |
STIEBER P, HASHOLZNER U, BODENMÜLLER H, et al. CYFRA21-1:a new marker in lung cancer[J]. Cancer, 1993, 72(3):707-713.
DOI URL |
| [5] |
DOYLE K, BUNCH D R. Reference intervals:past,present,and future[J]. Crit Rev Clin Lab Sci, 2023, 60(6):466-482.
DOI URL |
| [6] |
JONES G R D, HAECKEL R, LOH T P, et al. Indirect methods for reference interval determination-review and recommendations[J]. Clin Chem Lab Med, 2018, 57(1):20-29.
DOI URL |
| [7] | Clinical and Laboratory Standards Institute. Defining,establishing,and verifying reference intervals in the clinical laboratory;approved guideline-third edition[S]. EP28-A3c,CLSI, 2010. |
| [8] | 中国抗癌协会肿瘤标志专业委员会. 中国人群肺癌血清标志物临床应用及参考区间建立规范化流程专家共识[J]. 中国肿瘤临床, 2021, 48(22):1135-1140. |
| [9] | 中华人民共和国国家卫生健康委员会.WS/T 402—2024 临床实验室定量检验项目参考区间的制定[S]. 北京: 中华人民共和国国家卫生健康委员会, 2024. |
| [10] |
KASHIWABARA K, KISHI K, NAKAMURA H, et al. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure[J]. Intern Med, 1998, 37(11):917-921.
DOI URL |
| [11] |
STIEBER P, HOLDENRIEDER S. Lung cancer biomarkers-where we are and what we need[J]. Cancer Biomark, 2010, 6(3-4):221-224.
DOI URL |
| [12] |
CHEN S, LI M, WENG T, et al. Recent progress of biosensors for the detection of lung cancer markers[J]. J Mater Chem B, 2023, 11(25):5715-5747.
DOI PMID |
| [13] | EBERT W, DIENEMANN H, FATEH-MOGHADAM A, et al. Cytokeratin 19 fragment CYFRA21-1 compared with carcinoembryonic antigen,squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study[J]. Eur J Clin Chem Clin Biochem, 1994, 32(3):189-199. |
| [14] |
ZHAO B, ZHANG M, LIU D, et al. Establishment of reference interval for the tumour marker serum CYFRA21-1 in healthy Chinese Han ethnic adults[J]. Scand J Clin Lab Invest, 2018, 78(3):171-174.
DOI URL |
| [15] | ZHEN S H, WANG Y, GU C G, et al. Establishment of reference intervals for serum cytokeratin-19 fragment and neuron specific enolase by indirect method using data obtained from healthy Chinese population in Chengdu[J]. Clin Lab, 2019, 65(8):1425-1430. |
| [16] |
姬智, 邓玲艳, 李娇元, 等. 武汉地区健康成人血清细胞角蛋白19片段参考区间的建立[J]. 检验医学, 2021, 36(5):490-494.
DOI |
| [17] |
YOON S, LIM Y K, KIM H R, et al. Establishment of reference intervals of cytokeratin 19 fragment antigen 21-1 in Korean adults[J]. Ann Lab Med, 2023, 43(1):82-85.
DOI PMID |
| [18] | DAI Y, QU W, SANG S, et al. Reference intervals of cytokeratin-19 fragment(CYFRA21-1)in healthy adults in China[J]. Clin Lab, 2018, 64(1):123-133. |
| [1] | ZHANG Hui, YUAN Jingwen, ZHANG Chi. Adult reference ranges for platelet count and platelet-related parameters using fluorescence method in Wuhan [J]. Laboratory Medicine, 2025, 40(9): 892-896. |
| [2] | CAO Yue, SUN Qijuan, WANG Su, PAN Yiru, WANG Shiwen. Reference range of serum cystatin C in elders in Shanghai [J]. Laboratory Medicine, 2025, 40(8): 731-734. |
| [3] | CHEN Weilong, WANG Yongbing, CHEN Zegang. Correlation between ZBED3,CYFRA21-1,VEGF and short-term mortality risk in patients with advanced liver cancer [J]. Laboratory Medicine, 2025, 40(4): 338-343. |
| [4] | YU Jiajie, ZHANG Zhizhi, LUO Qingqiong, KE Xing. Predicting early colorectal tumor risk using a deep learning model based on multiple serum tumor markers [J]. Laboratory Medicine, 2025, 40(3): 253-258. |
| [5] | YU Xue, QI Aihong, LI Jinhui, QUAN Zhihui, LI Kui, QIU Yurong. Application role of an AI-patient based real time quality control intelligent monitoring platform for risk quality management of serum tumor markers [J]. Laboratory Medicine, 2025, 40(3): 264-270. |
| [6] | CHEN Yanqin, FAN Lina, YANG Dagan. Six indirect method algorithms for establishing the reference range of serum cystatin C for adults in Hangzhou and consistency analysis [J]. Laboratory Medicine, 2025, 40(11): 1047-1052. |
| [7] | LIU Chunyan, NIU Shumin, DENG Zhaohui, LIANG Mengjie, ZHANG Xin. Establishing the reference ranges for AFP,CEA,CA72-4 and CA19-9 in Urumqi region by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1053-1058. |
| [8] | PAN Yafang, ZHU Jing, SHAO Wenqi, YANG Jing, PAN Baishen, WANG Beili, GUO Wei. Establishment of reference range of serum CA50 for adults in Shanghai by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1059-1063. |
| [9] | LI Li, SHI Huaying, Zaxiyangzong , Dawazhuoma , CHEN Yanmei, YANG Chunjiao, WEN Honglin. Application of indirect method in establishing reference range of adult blood lipids in Lhasa [J]. Laboratory Medicine, 2025, 40(11): 1064-1069. |
| [10] | QI Xinglun, YAO Yifan, SHEN Shushi, YANG Zheng, ZHU Junjie, FAN Lina, YANG Dagan. Performance evaluation of different large language models in interpreting tumor marker determination reports [J]. Laboratory Medicine, 2025, 40(11): 1075-1081. |
| [11] | LEI Ming, ZHAI Li, WEI Ying, LIN Yichen, GUO Mengyue. Application of nomogram model based on clinical characteristics and serum tumor markers in differential diagnosis of benign and malignant lung lesions [J]. Laboratory Medicine, 2024, 39(10): 956-962. |
| [12] | DAI Jianmin, CHEN Nuo, WEI Jian. Changes of serum ProGRP,NSE and CYFRA21-1 levels among the patients with different stages of chronic kidney disease [J]. Laboratory Medicine, 2022, 37(9): 811-814. |
| [13] | GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine:from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312. |
| [14] | XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163. |
| [15] | XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||